KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) FCF Margin (2018 - 2025)

Historic FCF Margin for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to 53.76%.

  • BioNTech SE's FCF Margin rose 992400.0% to 53.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.2%, marking a year-over-year decrease of 603000.0%. This contributed to the annual value of 17.96% for FY2024, which is 1292200.0% down from last year.
  • Latest data reveals that BioNTech SE reported FCF Margin of 53.76% as of Q3 2025, which was up 992400.0% from 66.56% recorded in Q2 2025.
  • BioNTech SE's FCF Margin's 5-year high stood at 2655.87% during Q2 2023, with a 5-year trough of 400.33% in Q1 2025.
  • Moreover, its 5-year median value for FCF Margin was 26.1% (2021), whereas its average is 209.86%.
  • In the last 5 years, BioNTech SE's FCF Margin soared by 25310600bps in 2023 and then tumbled by -13227000bps in 2024.
  • Quarter analysis of 5 years shows BioNTech SE's FCF Margin stood at 4.32% in 2021, then skyrocketed by 423bps to 22.57% in 2022, then soared by 180bps to 63.2% in 2023, then crashed by -153bps to 33.34% in 2024, then surged by 261bps to 53.76% in 2025.
  • Its FCF Margin was 53.76% in Q3 2025, compared to 66.56% in Q2 2025 and 400.33% in Q1 2025.